| Expression pattern: |
DN |
| Associated gene: |
FOXO1, TGF-beta, Smad3, E-cadherin, N-cadherin, Vimentin, Ki-67 |
| Associated microRNA: |
miR-182-5p |
| Biological function: |
circGNAO1 acts as a tumor suppressor in HCC and inhibits proliferation, migration, invasion, EMT, tumor growth and liver metastasis. |
| Molecular mechanism: |
circGNAO1 functions as a miR-182-5p sponge to regulate FOXO1 expression and modulate TGF-beta/Smad3 signaling and EMT in HCC. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); EMT (inhibits); TGF-beta/SMAD (other); ceRNA regulation (other) |
| Detected method: |
Q
H
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; RNA-seq; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Luciferase Reporter Assay; Transfection; EdU Staining; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low circGNAO1 expression is associated with poorer overall survival and decreased circGNAO1 expression is correlated with tumor size and lymph node metastasis; circGNAO1 may be a potential therapeutic target for HCC. |
| Description: |
circGNAO1/hsa_circ_0105619 is a human GNAO1-derived circRNA that is downregulated in HCC tissues and cells. It suppresses HCC proliferation, migration, invasion, EMT, tumor growth and metastasis by sponging miR-182-5p and regulating FOXO1 within the circGNAO1/miR-182-5p/FOXO1 axis. Clinically, low circGNAO1 expression is associated with poorer overall survival, tumor size and lymph node metastasis, suggesting therapeutic relevance in HCC. |
| Confidence score: |
0.8792 |